Evidence map›Paper›PMID 42399572›Full record

ReviewIrish journal of medical science2026

Polypharmacy in glaucoma management: a narrative review.

Annie Paisansirikul, Sunee Chansangpetch

Abstract readReview
PubMed Publisher
In one paragraph

Review in Irish journal of medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Polypharmacy in glaucoma care.Irish journal of medical science · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Annie PaisansirikulPharmacy Department, King Chulalongkorn Memorial Hospital, The Thai Red Cross Society, 1873 Rama IV Rd, Pathum Wan, Pathum Wan District, Bangkok, 10330, Thailand. annie.p@chulahospital.org.ORCID http://orcid.org/0000-0002-6787-316X
Sunee ChansangpetchDepartment of Ophthalmology, Faculty of Medicine, Chulalongkorn University, 1873 Rama IV Rd, Pathum Wan, Pathum Wan District, Bangkok, 10330, Thailand.ORCID http://orcid.org/0000-0002-8996-2868

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGlaucoma is a leading cause of irreversible blindness worldwide. Treatment for glaucoma is typically lifelong and often requires multiple antiglaucoma medications (polypharmacy) to adequately control intraocular pressure, prevent disease progression, and preserve vision. While polypharmacy can enhance disease management, it also raises concerns about its potential long-term negative effects on patients;

methodsThis narrative review synthesizes recent literature from PubMed, ScienceDirect, and references published between January 2015 and October 2025 to examine the impact of polypharmacy on outcomes in glaucoma patients;

resultsEvidence suggests that polypharmacy is common in glaucoma care (ranging from 42% to 74%) and is linked to lower quality of life, higher healthcare costs, complex adherence challenges, increased risk of ocular surface disease, and potentially less favorable surgical outcomes;

conclusionsThese findings underscore the importance of balancing effective intraocular pressure reduction with minimizing medication burden through individualized management strategies. Further prospective longitudinal research is needed to clarify the longterm effects of polypharmacy in glaucoma care.

Indexed as

GlaucomaMedication adherenceOcular surface diseasePolypharmacyQuality of life

Identifiers

PMID42399572

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.